[go: up one dir, main page]

MX2018009998A - Analogos de cortistatina. - Google Patents

Analogos de cortistatina.

Info

Publication number
MX2018009998A
MX2018009998A MX2018009998A MX2018009998A MX2018009998A MX 2018009998 A MX2018009998 A MX 2018009998A MX 2018009998 A MX2018009998 A MX 2018009998A MX 2018009998 A MX2018009998 A MX 2018009998A MX 2018009998 A MX2018009998 A MX 2018009998A
Authority
MX
Mexico
Prior art keywords
human
advantageous
low
cortistatin analogs
administration
Prior art date
Application number
MX2018009998A
Other languages
English (en)
Inventor
Efrem Pelish Henry
Young Ahn Jae
D Shair Matthew
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of MX2018009998A publication Critical patent/MX2018009998A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se proporcionan derivados de cortistatina especificos con propiedades ventajosas para la administracion in vivo a un hospedero, incluyendo un humano, que lo necesite; estas especies novedosas tienen farmacocineticas ventajosas, baja toxicidad, baja a moderada actividad de hERG, y/u otras propiedades farmacologicas las cuales las hacen destacar de entre la clase de cortistatinas como candidatos superiores para la administracion humana.
MX2018009998A 2016-02-19 2016-12-21 Analogos de cortistatina. MX2018009998A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662297464P 2016-02-19 2016-02-19
PCT/US2016/068143 WO2017142621A1 (en) 2016-02-19 2016-12-21 Cortistatin analogs

Publications (1)

Publication Number Publication Date
MX2018009998A true MX2018009998A (es) 2018-12-10

Family

ID=59625333

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018009998A MX2018009998A (es) 2016-02-19 2016-12-21 Analogos de cortistatina.

Country Status (9)

Country Link
US (1) US20190062340A1 (es)
EP (1) EP3416970A4 (es)
JP (1) JP2019509996A (es)
KR (1) KR20180110134A (es)
CN (1) CN109415382A (es)
CA (1) CA3014581A1 (es)
MX (1) MX2018009998A (es)
RU (1) RU2018133138A (es)
WO (1) WO2017142621A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024057306A1 (en) * 2022-09-14 2024-03-21 Tactile World Ltd Systems and methods for alleviation of one or more psychiatric disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008079028A1 (en) * 2006-12-22 2008-07-03 Industrial Research Limited Azetidine analogues of nucleosidase and phosphorylase inhibitors
EP2334686B1 (en) * 2008-08-28 2019-02-27 President and Fellows of Harvard College Cortistatin analogues and syntheses therof
KR20130083386A (ko) * 2010-05-20 2013-07-22 에프. 호프만-라 로슈 아게 피롤로[2,3-ｂ]피라진-7-카복스아마이드 유도체 및 ＪＡＫ 및 ＳＹＫ 억제제로서의 그의 용도
KR20160101162A (ko) * 2013-12-24 2016-08-24 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 코르티스타틴 유사체 및 그의 합성 및 용도

Also Published As

Publication number Publication date
EP3416970A1 (en) 2018-12-26
RU2018133138A (ru) 2020-03-19
JP2019509996A (ja) 2019-04-11
WO2017142621A1 (en) 2017-08-24
CA3014581A1 (en) 2017-08-24
EP3416970A4 (en) 2019-07-24
CN109415382A (zh) 2019-03-01
US20190062340A1 (en) 2019-02-28
KR20180110134A (ko) 2018-10-08

Similar Documents

Publication Publication Date Title
PH12018501351A1 (en) Cortistatin analogs and uses thereof
NI201700096A (es) Derivados de 4h-pirrol[3, 2-c]piridin-4-ona
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
MX2016008448A (es) Conjugados de var2csa-farmaco.
EP4523705A3 (en) Glucagon derivative and a composition comprising a long acting conjugate of the same
CR20160501A (es) Derivados de quinoxalina útiles como amortiguadores del receptor del factor de crecimiento de fibroblastos (fgfr) cinasa
HK1222205A1 (zh) 由多能干细胞产生的光感受器和光感受器袓细胞
PH12016501962A1 (en) Macrocyclic pyridine derivatives
MX373716B (es) Compuesto de pirazol-amida y sus usos farmaceuticos.
MX2016009794A (es) Derivado de sulfonamida heterociclico y medicina que comprende el mismo.
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof
BR112015021586A2 (pt) formulações de morfina
MY181641A (en) Amino pyran ring derivative and composition and use thereof
MX2016012451A (es) Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina.
UY37193A (es) Nuevos compuestos antivíricos
CL2017001100A1 (es) Nuevas triazolo[4,5-d]pirimidinas
UY35997A (es) Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
MX2018015872A (es) Derivados de benzodioxano y su uso farmaceutico.
WO2016048861A3 (en) Heterocyclic compounds and use thereof
TN2016000490A1 (en) Naphthyridinedione derivatives.
CL2018003610A1 (es) Nuevos derivados de [1,2,3]triazolo[4,5-d]pirimidina.
MX2017009292A (es) Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3.
TN2017000342A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
MX2018004696A (es) Analogos de epotilona, metodos de sintesis, metodos de tratamiento y conjugados con farmacos de los mismos.